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Background: Toxoplasmosis is an important zoonosis, being a cause of congenital disease and abortion in animals
and humans. DNA vaccination as a promising vaccine remains a challenge for an improved delivery system.
Methods: In this study, attenuated Salmonella typhimurium BRD509 was used to deliver a DNA vaccine encoding
several epitopes, derived from the tachyzoite proteins SAG1, GRA1, ROP2, GRA4 and bradyzoite proteins SAG2C,
SAG2X of Toxoplasma gondii and A2/B subunit of cholera toxin. The recombinant plasmids were electroporated into
attenuated Salmonella typhimurium. Humoral and cellular immune responses were evaluated for BALB/c mice
administered with this attenuated recombinant Salmonella vaccine via the oral and nasal route or by intramuscular
injection with DNA plasmid directly.
Results: High IgG levels were present in the mice immunized intramuscularly, while IgA levels were higher in the
oral and nasal immunization groups. Furthermore, cellular immunity was activated in oral immunization groups
with 60% survival rate following challenge with high virulent RH strain.
Conclusions: The results from this study indicate that a DNA vaccine encoding multi-epitopes of T. gondii delivered
by attenuated Salmonella is promising.
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Toxoplasma gondii is a single-cell obligate intracellular
protozoan, which is widely prevalent in humans and ani-
mals [1,2]. This parasite is of major medical and veterin-
ary importance, being a cause of congenital disease and
abortion [3,4]. Despite many efforts and significant ad-
vances in the understanding of the immune responses
that occur after infection by T. gondii, animal experi-
ments have shown that the effect of monovalent antigen
vaccine is not ideal [5-7]. Therefore, the development of
a variety of antigen combinations for different stages of
life cycle, especially epitopes from tachyzoites and* Correspondence: conghua@sdu.edu.cn; zhiyu.wang@sdu.edu.cn
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reproduction in any medium, provided the orbradyzoites are likely to be needed for full protection
[8-11]. We constructed a DNA vaccine encoding five
epitopes of T. gondii previously. The vaccination injected
intramuscularly into BALB/c resulted in an improve-
ment of the humoral and cellular immune response in
immunized mice, but there was only 20% survival rate
achieved in vaccinated mice [12]. In order to broaden
the immunogenicity, we intend to include more epitopes
from various proteins of tachyzoites and bradyzoites in
the vaccine construction. Other than epitopes from
tachyzoite proteins SAG1, GRA1, ROP2, GRA4, epitopes
from bradyzoite proteins SAG2C, SAG2X were also in-
cluded [13,14].
However, DNA vaccines have been used to inject
intramuscularly as naked DNA using a gene gun and
by subcutaneous inoculation. After vaccination, only a
limited amount of DNA reaches professional APCstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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mune response and to improve protection from immu-
nized mice remains to be determined. Recombinant
Salmonella have been used as vaccine vectors to de-
liver both DNA and protein vaccines from a wide
variety of bacterial, viral and parasitic sources [16,17].
Attenuation virulence bacteria, which can penetrate
host cells delivering vaccine antigen to APCs, can be
used effectively to transport immunogens [18,19].
In this study, a recombinant attenuated Salmonella
DNA vaccine encoding multi-epitopes of T. gondii and
A2/B subunits of cholera toxin was constructed. The im-
munity induced by this attenuated recombinant Salmon-
ella vaccine administered orally and nasally in BALB/c
mice was compared to immunity induced by a plasmid
DNA vaccine injected into mice intramuscularly. Protec-
tion against challenge with high virulent RH strain of
T. gondii was evaluated.Methods
Parasites and bacterial strain
Tachyzoites of the high virulent RH strain of T. gondii
were cryopreserved in our laboratory. Parasites were
maintained by serial intraperitoneal passage in BALB/c
mice. Tachyzoites were harvested from the peritoneal
fluid of mice after 72 h, and used to challenge immu-
nized mice.
Salmonella typhimurium strain BRD509 is an aroA−
and aroD− mutant of SL 1344 [20]. This was kindlyFigure 1 Construction of recombinant attenuated Salmonella carrying
derived from T. gondii and A2/B subunits of cholera toxin. (A) The diag
Gel electrophoresis analysis of pVAX1-MEG-CTXA2/B plasmid encoding multi-ep
Lane M2: DNA Marker DL2000, Lane1: pVAX1-MEG-CTXA2/B plasmid digested b
EcoR I, Lane 3: pVAX1-MEG-CTXA2/B digested by Hind III and Kpn I, Lane4: PCRprovided by Dr. Jifeng Bian, the Department of Molecular
Biology, Shandong University.
Construction of recombinant Salmonella
The oligonucleotides of multi-epitope genes (MEG) were
designed based on the T. gondii peptide sequences: SAG1-I
59–67 (TCPDKKSTA), SAG1-II 246–255 (ILPKLTENPW),
GRA1 176–186(DTMKSMQRDED), ROP2 200–215 (GDV
VIEELFNRIPETS), GRA4 235–243 (SGLTGVKDS), SAG
2C 36–44 (SQFLSLSLL), SAG2X 215–223 (AAGTTAT
AV). The construction of pVAX1-MEG-CTXA2/B was
shown in Figure 1.
Attenuated recombinant Salmonella carrying pVAX1-
MEG-CTXA2/B was generated by electroporation. pVAX1-
MEG-CTXA2/B plasmid was transferred into 100 μl
competent S. typhimurium BRD509 in the condition of
2.5 kV, 25 uF, 5 ms. To produce inocula, recombinant
Salmonella were incubated overnight at 37°C until an
OD600 of 0.8 was reached, then washed and resuspended
in PBS to a final density of approximately 1–5 × 109 cfu.
Vaccinations and challenges
SPF BALB/c female mice (6–8 weeks old) were used in the
immunization and parasite challenge. They were purchased
from The Laboratory Animal Center of Shandong
University. All studies were conducted with Animal Care
and Use Committee of Shandong University approval.
The mice were randomly divided into intraoral, intranasal
and intramuscular immunization groups (30 mice per
group). Table 1 summarizes the treatments performed inpVAX1-MEG-CTXA2/B plasmid encoding multi-epitope genes
ram of the construction of recombinant attenuated Salmonella. (B)
itope genes of Toxoplasma gondii. Lane M1: DNA Marker D, L 100 + 6000,
y EcoR I, Lane 2: pVAX1-MEG-CTXA2/B plasmid digested by Hind III and
product of CTXA2/B.
Table 1 Summary of treatments performed in the BALB/c mice
Groups Route of administration Treatmentsa Mice number
Total mice In HIb and CMIc In challenged
I Intramuscular vaccination 100 μl PBS 10 3 7
100 μg pVAX1 10 3 7
100 μg pVAX1-MEG-CTXA2/B 10 3 7
II Intranasal vaccination 200 μl BRD509 10 3 7
200 μl BRD509/pVAX1 10 3 7
200 μl BRD509/pVAX1-MEG-CTXA2/B 10 3 7
III Intraoral vaccination 50 μl BRD509 10 3 7
50 μl BRD509/pVAX1 10 3 7
50 μl BRD509/pVAX1-MEG-CTXA2/B 10 3 7
aThe mice were randomly divided into intramuscular, intranasal and intraoral immunization groups (30 mice per group). For the intramuscular group, the mice
were injected 100 μl 1 μg/μl recombinant plasmid or empty plasmid in the quadriceps muscle; For the nasal group, each mouse was given a nasal drip of 50 μl
109 cfu/ml Salmonella bacteria with recombinant plasmid or empty plasmid; The oral group was administrated 200 μl 109 cfu / ml Salmonella bacteria with
recombinant plasmid or empty plasmid orally; Each group also had 10 mice which were treated with Salmonella without plasmid or saline as negative control.
Mice were vaccinated three times at 2 week intervals.
bHumoral immunity (HI) was tested by collecting sera from three immunized mice in each group.
cCellular immunity (CMI) was evaluated by splenocytes from three immunized mice per group 2 weeks after the last immunization.
dFour weeks after the last immunization, immunized mice were challenged intraperitoneally with 1 × 103 tachyzoites of T. gondii RH strain.
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tervals. Blood was collected by orbital plexus puncture and
sera were stored at −70 °C for further analysis.
For challenge study, immunized mice were challenged
intraperitoneally with 1 × 103 tachyzoites of RH strain T.
gondii 4 weeks after the last immunization. The survival
time and the survival rate was measured.Measurement of humoral antibodies response
To measure T. gondii-specific total IgG and IgA, plates
(Dursley, UK) were coated with 10 ug/ml solution of
STAg at 4°C overnight. Sera were diluted in 1% PBST-20
(1:100) and incubated in the plates for 1 h at room
temperature (RT). After washing the plates, Horseradish
peroxidase (HRP)-conjugated goat anti-mouse IgG, IgA
(SouthernBiotech, USA) were further incubated for 1 h
at RT. Peroxidase activity was revealed by 3,3′,5,5′-
tetramethylbenzidine (TMB, 10 mg/ml) and stopped
by adding 50 μl of 2 M H2SO4. The optical density
(OD) was read out at 450 nm in a microplate reader
(Bio-TEK, USA).Proliferation assays
Spleens from three immunized mice per group were re-
moved 2 weeks after the last immunization. The spleno-
cytes were adjusted to a concentration of 5 × 106 cells/
ml in DMEM with 10% FCS. The suspension of 100 μl
in each well was cultured with STAg (10 μg/ml), puri-
fied rMEG protein (50 μg/ml) or concanavalin A (Con
A, 5 μg/ml; Sigma). Cell proliferative activity was mea-
sured according to instructions described in a previous
study [21].T lymphocyte subsets analysis
Cells were stained with FITC-labeled anti-mouse CD8+
monoclonal antibody and PE-labeled anti-mouse CD4+
monoclonal antibody, T lymphocyte subsets were mea-
sured using flow cytometry (Beckman Coulter, USA).
Cytokine assays
Splenocytes from immunized mice were cultured with
rMEG protein as described for lymphocyte proliferation
assays. Commercial ELISA kits (mouse IL-4 OptEIA, IL-
5 OptEIA, IFN-γ OptEIA, IL-2 OptEIA, Endogen, USA)
were used according to the manufacturer’s instructions
to assay cytokine levels in culture supernatants obtained
at 24 h for IL-4, at 36 h for IL-5, at 72 h for IL-2 and at
96 h for IFN-γ.
Statistical analysis
The statistically significant differences between groups
were calculated with one-factor analysis of variance
(ANOVA). Differences were considered to be signifi-
cant with p < 0.05.
Results
Construction of recombinant Salmonella
The diagram for multi-epitope DNA vaccine of T. gondii
is shown on Figure 1A. Recombinant Salmonella carry-
ing pVAX1-MEG-CTXA2/B plasmid were identified by
enzyme digestion, by PCR (Figure 1B) and further con-
firmed by sequencing.
Humoral immune response
IgG antibody levels in mouse serum indicates that pVAX1-
MEG-CTXA2/B DNA plasmid inoculated intramuscularly
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BRD509/pVAX1-MEG-CTXA2/B orally and intranasally,
p < 0.05 (Figure 2A). On the other hand, higher levels of
anti-T. gondii IgA were detected in the serum of mice im-
munized with BRD509/pVAX1-MEG-CTXA2/B via the
oral and nasal route than in the serum of mice injected
intramuscularly with pVAX1-MEG-CTXA2/B plasmid
(p < 0.05) (Figure 2B).
Cellular immune response analysis
CD4+ and CD8+ T lymphocyte subsets in immunized mice
were assayed by flow cytometry. Table 2 shows the percent-
age of CD4+ and CD8+ T-cell. The percentage of CD8+
T cells in mice immunized intramuscularly with pVAX1-
MEG-CTXA2/B plasmid was 28.54 ± 0.92%. A even higher
percentage of CD8+ T cells, 30.01 ± 1.78%, was achieved in
mice immunized intranasally with BRD509/ pVAX1-MEG-
CTXA2/B. The highest percentage of CD8
+ T-cell, 35.55 ±
0.70%, was achieved in mice immunized orally with
BRD509/pVAX1-MEG-CTXA2/B (Table 2). Culture su-
pernatants from antigen-stimulated splenocytes from mice
in these groups were quantified with sandwich ELISA forFigure 2 Specific humoral response to native T. gondii antigens in mi
using ELISA 2 weeks after the last immunization. (A) Total Anti-T. gond
BALB/c mice via three different immunized routes: i.o.( intraoral); i.n. (intranTh1 and Th2 cytokines. As shown in Table 3, culture
supernatant cytokines from the mice vaccinated intramus-
cularly with pVAX1-MEG- CTXA2/B demonstrated
preferential production of IFN-γ and IL-2, which were
significantly higher than that of control groups (p < 0.05).
The amounts of IFN-γ and IL-2 were significantly higher in
the mice via oral and intranasal immunization with recom-
binant Salmonella BRD509 than the mice immunized intra-
muscularly (p = 0.02). However, the levels of IL-4 and IL-5
produced by immunized mice were low, and no statistically
significant differences were present between vaccinated
groups and control groups (p > 0.05). Furthermore, anti-
gen specific lymphocyte proliferation activity was highly
enhanced for BRD509/pVAX1-MEG-CTXA2/B oral and
intranasal immunization groups than for the pVAX1-MEG-
CTXA2/B intramuscular immunization group (p < 0.05).
Challenge study
Four weeks after the last immunization, mice were chal-
lenged with 100 ul 1 × 103 tachyzoites of T. gondii RH
strain intraperitoneally. All the control mice died. Mice
treated with saline died within 4 days. Mice immunizedce immunized with multi-epitope DNA vaccine was measured
ii IgG; (B) Anti-T. gondii IgA were tested by sera diluted 1:200 from
asal); i.m. (intramuscular).
Table 2 CD4+, CD8
+ subtypes of T cells from immunized
















































aMice were immunized by three immunization routes, intramuscular, intraoral,
intranasal, on day 0 and day 14 and day 28 with different
immunization regimens.
bThe splenocyte culture supernatants taken from mice (n = 3, each group)
2 weeks after the last immunization were stained with FITC-labeled anti-mouse
CD8+ monoclonal antibody and PE-labeled anti-mouse CD4+ monoclonal
antibody, T lymphocyte subsets were measured using flow cytometry.
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Mice treated orally with empty Salmonella died within
8 days. While there was a 20% survival rate (2/10) for the
mice immunized with pVAX1-MEG-CTXA2/B plasmid
intramuscularly. The recombinant Salmonella BRD509/
pVAX1-MEG-CTXA2/B intranasal immunization group
had 40% survival rate (4/10) after 10 days. The highest
survival rate of 60% (6/10) was achieved in the mice orallyTable 3 Cell proliferative assay and cytokine production in th
Immunization routea Immunization regimen C
I
Intramuscular vaccination Saline 1
pVAX1 1
pVAX1-MEG-CTXA2/B 9
Intranasal vaccination BRD509 1
BRD509/pVAX1 1
BRD509/ pVAX1-MEG-CTXA2/B 1
Intraoral vaccination BRD509 1
BRD509/pVAX1 1
BRD509/ pVAX1-MEG-CTXA2/B 1
aMice were immunized by three immunization routes, intramuscular, intraoral, intra
bThe splenocyte culture supernatants taken from mice (n = 3, each group) 2 weeks
sandwich ELISA obtained at 24 h for IL-4, at 36 h for IL-5, at 72 h for IL-2 and 96 h f
cThe results of proliferation assays are expressed as the stimulation index (SI), calcu
stimulated cultures and the mean counts per min for triplicate unstimulated culture
as significant.immunized with recombinant Salmonella BRD509/
pVAX1-MEG-CTXA2/B (Figure 3).
Discussion
Recently, considerable efforts have been devoted to the
development of nucleic acid vaccine to protect against
T. gondii [22-25]. However, because of the complexity of
the parasite life cycle and the variability of the parasite
antigens, multi-epitope vaccines have become an attract-
ive strategy for development of vaccines against this
parasite [26-28]. In this study, a DNA vaccine encoding
seven epitopes of T. gondii, derived from the tachyzoite
proteins SAG1, GRA1, ROP2, GRA4 and bradyzoite pro-
teins SAG2C, SAG2X of T. gondii, were constructed and
linked to A2/B subunit of cholera toxin.
However, DNA vaccine as a promising vaccine remains
a challenge for an improved delivery system. Mucosal
vaccines can enhance mucosal and systemic humoral
immunity especially for intracellular parasites such as T.
gondii [29,30]. Thus, the best way for a vaccine to induce
mucosal immunity is directly by inoculation of the mu-
cosal surface. In this study, attenuated strains of S. typhi-
murium BRD509 were used as vaccine vectors to deliver
heterologous antigens to the mucosal surface of the
vaccine recipients [31,32]. A recombinant attenuated S.
typhimurium vaccine encoding a multi-epitope gene of
T. gondii was constructed. The mice were given inocula-
tions via oral, nasal, or muscular routes. Immune responses
induced by oral or nasal immunization with attenuated
recombinant Salmonella BRD509 vaccines were com-
pared to immune response induced by immunization
with the plasmid pVAX1-MEG-CTXA2/B DNA vaccine
intramuscularly.
The results showed intramuscular immunization of mice
induced higher levels of IgG antibodies than attenuatede splenocyte cultures obtained from immunized mice
ytokine production (pg/ml)b
L-2 IFN-γ IL-4 IL-5 SIc
2 ± 3 13 ± 8 <10 <10 0.23
6 ± 4 15 ± 5 11 ± 8 <10 0.51
3 ± 21 385 ± 64 15 ± 7 13 ± 6 1.61
3 ± 4 14 ± 5 <10 17 ± 5 0.75
4 ± 7 15 ± 6 <10 19 ± 5 1.07
05 ± 30 412 ± 24 23 ± 6 <10 2.12
2 ± 5 15 ± 4 <10 16 ± 8 0.75
5 ± 7 18 ± 4 <10 16 ± 7 1.45
21 ± 36 507 ± 16 <10 12 ± 4 2.85
nasal on day 0 and day 14 and day 28 with different immunization regimens.
after the last immunization were examined for cytokine production by
or IFN-γ.
lated as the ratio between the mean counts per minute (cpm) for triplicate
s. SI values 2.5-fold greater than the SI of the control groups were considered
Figure 3 Survival curves of immunized mice after challenge with 103 tachyzoite forms of RH T. gondii strain 4 weeks after the last
immunization. (A) Intramuscular immunization group, the mice were injected with 100 μl 1 μg/μl recombinant plasmid, empty plasmid or PBS
in the quadriceps muscle; (B) Nasal immunization group, each mouse was given a nasal drip of 50 μl 109 cfu/ml Salmonella bacteria with
recombinant plasmid, empty plasmid or empty bacteria; (C) Oral immunization group, the mice were administrated orally with 200 μl 109 cfu/ml
Salmonella bacteria with recombinant plasmid, empty plasmid, or empty bacteria.
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nasal routes. However, the attenuated recombinant Salmon-
ella oral and intranasal immunization induced higher levels
of IgA antibodies than intramuscular immunization. IgA is
important in mucosal immunity to oral infection with toxo-
plasma cysts. Since antibodies of this isotype are important
in preventing re-infection with T. gondii, inducing IgA may
be a major strategic aspect of vaccine development [33,34].
Major mechanisms by which immunocompetent hosts
control T. gondii infections is thought to be the strong
and persistent cell-mediated immunity elicited by para-
sites [35,36]. In this study, splenocyte proliferation was
enhanced in mice immunized by all three routes. Prolifera-
tion activity was significantly enhanced in mice immunized
with recombinant attenuated Salmonella BRD509 via oral
and nasal routes.
Both CD4+ and CD8+ T cell subsets play a central role
in the establishment of protective immunity in hosts. In
this study, CD4+ and CD8 + T lymphocytes subsets from
immunized mice were assayed by flow cytometry. There
was a marked increase in the percentage of CD8+ T-cells
in mice immunized with the recombinant attenuated
Salmonella BRD509 vaccine perorally. As we know, the
memory T-cell consists of CD4+ and CD8+ T-cells, which
can rapidly acquire effector functions to kill infected cells
and secrete inflammatory cytokines that inhibit replicationof the pathogen. Effector CD4+ T-cells enhance CD8+ T
cells develope and help B-cell responses through the activa-
tion of antigen-presenting cells or the secretion of cyto-
kines, such as IFN-γ, IL-2 [37,38]. Compared with the
intramuscular immunization DNA vaccine, introduction of
attenuated Salmonella further enhanced Th1 cell-mediated
immunity with higher levels of IFN-γ and IL-2 but low
levels of IL-4 and IL-5. These results clearly demon-
strate that attenuated Salmonella BRD509 can signifi-
cantly augment Th1-type cellular immune responses
in BALB/c mice. Both T-cell subsets are important
sources of IFN-γ. Optimal protective CD8+ T cell
responses depend on the ability of CD4+ T-cells to pro-
vide the growth factor IL-2.
In this study, a highly virulent RH strain of T. gondii
was used for challenge study. When challenged with le-
thal doses of T. gondii (1 × 103) all three immunization
groups prolonged survival time compared to control
mice. Especially, mice immunized perorally had a 60%
survival rate. There was somewhat less enhancement
of survival (40%) following intranasal immunization,
while only a 20% survival rate was achieved following
intramuscular immunization. In the future, a cyst-
forming PRU strain of T. gondii will be used to evaluate
the protective potency of this recombinant Salmonella
vaccine via the mucosal immunization route.
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In summary, multi-epitope vaccines delivered by attenu-
ated Salmonella are a promising way to elicit protective
immune responses. Compared to intramuscular injec-
tion, oral and nasal immunizations with recombinant
Salmonella elicits both systemic and mucosal immune
responses, accompanied by a significant increase in sur-
vival rates in vaccinated mice after challenge with highly
virulent parasites. The results from this study should
contribute to development of highly protective mucosal
vaccines against T. gondii.
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